<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118300</url>
  </required_header>
  <id_info>
    <org_study_id>CASE9804</org_study_id>
    <secondary_id>P30CA043703</secondary_id>
    <secondary_id>CASE-9804</secondary_id>
    <secondary_id>CWRU-010514</secondary_id>
    <nct_id>NCT00118300</nct_id>
  </id_info>
  <brief_title>Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer</brief_title>
  <official_title>Phase I Study of Capecitabine (Xeloda) and Radiation Therapy in Patients With Locally Advanced Cervical and Pelvic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop&#xD;
      the growth of tumor cells, either by killing the cells or by stopping them from dividing.&#xD;
      Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells.&#xD;
      Internal radiation uses radioactive material placed directly into or near a tumor to kill&#xD;
      tumor cells. Giving chemotherapy together with radiation therapy may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of capecitabine when&#xD;
      given together with radiation therapy in treating patients with locally advanced cervical&#xD;
      cancer or other pelvic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose and dose-limiting toxicity of capecitabine when&#xD;
           given in combination with pelvic external beam radiotherapy and intracavitary&#xD;
           brachytherapy in patients with primary or recurrent locally advanced cervical cancer or&#xD;
           other pelvic malignancy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the clinical anti-tumor response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine adverse clinical sequelae in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study of capecitabine.&#xD;
&#xD;
      Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in&#xD;
      weeks 1-5 and receive 1 or 2 applications of low-dose rate intracavitary brachytherapy in&#xD;
      weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly&#xD;
      in weeks 4-8. Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5&#xD;
      and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      NOTE: *No external beam radiotherapy is administered on the day of HDR brachytherapy. If the&#xD;
      majority of external beam radiotherapy has been administered, HDR brachytherapy may be&#xD;
      administered in 2 applications per week (separated by at least 72 hours) in order to complete&#xD;
      all treatment by week 8.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of capecitabine until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. A minimum of 6 patients are treated at the&#xD;
      MTD.&#xD;
&#xD;
      After completion of study treatment, patients are followed at 1 month, every 3 months for 1&#xD;
      year, every 6 months for 2 years, and then annually for 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 4-24 patients will be accrued for this study within 2-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Competing studies&#xD;
  </why_stopped>
  <start_date>April 2005</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease response measured prior to brachytherapy and at 1 month after completion of study treatment</measure>
    <time_frame>1 month after completion of study treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity as measured by CTC v 3.0 weekly</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Cervical Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Vaginal Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>brachytherapy</intervention_name>
    <description>1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.</description>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed cervical cancer or other pelvic malignancy, including&#xD;
             vaginal, endometrial, or ovarian cancer&#xD;
&#xD;
               -  Primary or recurrent disease&#xD;
&#xD;
               -  Locally advanced disease, defined as the following:&#xD;
&#xD;
                    -  Stage IB2-IVA (for cervical or vaginal cancer)&#xD;
&#xD;
                    -  Any non-extra pelvic metastatic stage (for endometrial or ovarian cancer)&#xD;
&#xD;
          -  Not amenable to curative surgical resection alone&#xD;
&#xD;
          -  Bidimensionally measurable or clinically evaluable disease&#xD;
&#xD;
          -  Refused or ineligible for weekly IV cisplatin chemotherapy due to renal insufficiency,&#xD;
             prior platinum adverse sensitivity, pre-existing neuropathy, or concurrent co-morbid&#xD;
             illness&#xD;
&#xD;
          -  No histologically confirmed or clinically suspicious (≥ 1 cm) para-aortic&#xD;
             lymphadenopathy&#xD;
&#xD;
          -  No brain metastases or primary brain tumors&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over (80 and under for second and third dose-escalation levels)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  GOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 2 times upper limit of normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine normal OR&#xD;
&#xD;
          -  Creatinine clearance ≥ 30 mL/min*&#xD;
&#xD;
          -  No proteinuria or clinically significant impaired renal function NOTE: *Creatine&#xD;
             clearance testing required in patients &gt; 60 years of age&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No symptomatic New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Gastrointestinal&#xD;
&#xD;
          -  Able to swallow oral medication&#xD;
&#xD;
          -  No bowel obstruction&#xD;
&#xD;
          -  No malabsorption illness&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No known hypersensitivity to capecitabine or fluorouracil&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other active invasive malignancy&#xD;
&#xD;
               -  Prior malignancy in remission for ≥ 6 months that is not currently being treated&#xD;
                  allowed&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)&#xD;
&#xD;
          -  Prior chemotherapy for a non-gynecologic malignancy or in the adjuvant setting allowed&#xD;
&#xD;
          -  No prior capecitabine&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior adjuvant hormonal therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  Prior radiotherapy for a non-gynecologic malignancy allowed&#xD;
&#xD;
          -  No prior low abdominal or pelvic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior investigational anticancer agents and recovered&#xD;
&#xD;
          -  No prior anticancer treatment that contraindicates study therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Kunos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.gov/ct2/results?term=case9804</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <last_update_submitted>July 7, 2011</last_update_submitted>
  <last_update_submitted_qc>July 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charles Kunos, MD, PhD</name_title>
    <organization>Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center</organization>
  </responsible_party>
  <keyword>stage III cervical cancer</keyword>
  <keyword>stage IVA cervical cancer</keyword>
  <keyword>recurrent cervical cancer</keyword>
  <keyword>stage III endometrial carcinoma</keyword>
  <keyword>recurrent endometrial carcinoma</keyword>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>stage III ovarian germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>stage III vaginal cancer</keyword>
  <keyword>stage IVA vaginal cancer</keyword>
  <keyword>recurrent vaginal cancer</keyword>
  <keyword>ovarian sarcoma</keyword>
  <keyword>ovarian stromal cancer</keyword>
  <keyword>stage IV endometrial carcinoma</keyword>
  <keyword>stage IB cervical cancer</keyword>
  <keyword>stage IIA cervical cancer</keyword>
  <keyword>stage IIB cervical cancer</keyword>
  <keyword>stage II vaginal cancer</keyword>
  <keyword>stage I vaginal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Vaginal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

